Dianthus Therapeutics, Inc. Common Stock DNTH
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T00:47:31.124Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T21:24:53.308171627Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-13T00:47:30.597564+00:00
Dianthus Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 121.67 | 179.7% | 32.0% | |||
| 25Δ | 109.22 | 131.3% | 18.8% | 86.53 | 91.2% | 10.1% |
| 30Δ | 103.14 | 102.1% | 12.3% | 88.57 | 85.7% | 8.3% |
| 35Δ | 99.45 | 81.8% | 8.4% | 90.44 | 81.8% | 6.9% |
| 40Δ | 97.52 | 68.9% | 6.4% | 91.88 | 81.6% | 6.0% |
| 45Δ | 95.59 | 56.1% | 4.3% | 93.32 | 81.4% | 5.2% |
| 50Δ | 94.56 | 50.1% | 3.4% | 94.76 | 81.2% | 4.4% |
| 55Δ | 93.94 | 47.0% | 3.0% | 96.31 | 81.8% | 3.8% |
| 60Δ | 93.31 | 43.9% | 2.6% | 97.88 | 82.5% | 3.2% |
| 65Δ | 92.68 | 40.9% | 2.1% | 99.46 | 83.2% | 2.6% |
| 70Δ | 92.05 | 37.8% | 1.7% | 102.25 | 92.3% | 2.3% |
| 75Δ | 91.43 | 34.8% | 1.3% | 105.88 | 105.3% | 2.1% |
| 80Δ | 90.80 | 31.7% | 0.9% | |||
20Δ
- Pseudo strike
- 121.67
- IV
- 179.7%
- B/E move
- 32.0%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 109.22
- IV
- 131.3%
- B/E move
- 18.8%
- Pseudo strike
- 86.53
- IV
- 91.2%
- B/E move
- 10.1%
30Δ
- Pseudo strike
- 103.14
- IV
- 102.1%
- B/E move
- 12.3%
- Pseudo strike
- 88.57
- IV
- 85.7%
- B/E move
- 8.3%
35Δ
- Pseudo strike
- 99.45
- IV
- 81.8%
- B/E move
- 8.4%
- Pseudo strike
- 90.44
- IV
- 81.8%
- B/E move
- 6.9%
40Δ
- Pseudo strike
- 97.52
- IV
- 68.9%
- B/E move
- 6.4%
- Pseudo strike
- 91.88
- IV
- 81.6%
- B/E move
- 6.0%
45Δ
- Pseudo strike
- 95.59
- IV
- 56.1%
- B/E move
- 4.3%
- Pseudo strike
- 93.32
- IV
- 81.4%
- B/E move
- 5.2%
50Δ
- Pseudo strike
- 94.56
- IV
- 50.1%
- B/E move
- 3.4%
- Pseudo strike
- 94.76
- IV
- 81.2%
- B/E move
- 4.4%
55Δ
- Pseudo strike
- 93.94
- IV
- 47.0%
- B/E move
- 3.0%
- Pseudo strike
- 96.31
- IV
- 81.8%
- B/E move
- 3.8%
60Δ
- Pseudo strike
- 93.31
- IV
- 43.9%
- B/E move
- 2.6%
- Pseudo strike
- 97.88
- IV
- 82.5%
- B/E move
- 3.2%
65Δ
- Pseudo strike
- 92.68
- IV
- 40.9%
- B/E move
- 2.1%
- Pseudo strike
- 99.46
- IV
- 83.2%
- B/E move
- 2.6%
70Δ
- Pseudo strike
- 92.05
- IV
- 37.8%
- B/E move
- 1.7%
- Pseudo strike
- 102.25
- IV
- 92.3%
- B/E move
- 2.3%
75Δ
- Pseudo strike
- 91.43
- IV
- 34.8%
- B/E move
- 1.3%
- Pseudo strike
- 105.88
- IV
- 105.3%
- B/E move
- 2.1%
80Δ
- Pseudo strike
- 90.80
- IV
- 31.7%
- B/E move
- 0.9%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 70.04% | |
| 70.98% | |
| 70.06% | |
| 70.90% | |
| 70.20% | |
| 71.49% | |
| 70.52% | |
| 72.31% | |
| 71.06% | |
| 70.22% |
Biotechnology
DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha…
More →DRUG
Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies for central nervous system…
More →DSGN
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad,…
More →DTIL
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
More →DYN
Description unavailable
More →EDIT
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is…
More →